NICE plans appraisal for Pfizer's Inlyta in RCC where others have failed
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, wants to look at Pfizer's Inlyta (axitinib) for treating advanced renal cell carcinoma (RCC) after prior systematic treatment has failed. The drug could face a rocky ride if previous NICE appraisals for second-line RCC options are anything to go by. The institute has so far turned down Bayer's Nexavar (sorafenib), Pfizer's Sutent (sunitinib) and Novartis' Afinitor (everolimus) because of doubts over cost-effectiveness.